All In Biotech

Drug Trial Radar · NCT04584710

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age ≥65 Years

Last checked: Nov 19, 2026Latest source record: Feb 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 13, 2020

Primary completion

Feb 2021

Study completion Feb 2021

Sponsor

Lead sponsor
Restorbio Inc.Industry
Sponsor type
Industry
Collaborators
National Institute on Aging (NIA)
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.

Conditions

  • Covid19

Interventions

  • RTB101Drug

    Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks

  • PlaceboDrug

    Oral matching placebo once daily for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 yearsTime frame: Beginning of randomization through Week 2

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Connecticut, UConn Center on Aging

    Farmington, Connecticut

  • Hebrew Senior Life, Marcus Institute for Aging Research

    Roslindale, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.